T1	intervention 4 34	Prosigna gene expression assay
T2	eligibility 105 156	premenopausal high-risk patients with breast cancer
T3	ethinicity 565 571	Danish
T4	control 695 717	no systemic treatment,
T5	eligibility 637 691	premenopausal women with high-risk early breast cancer
T6	total-participants 861 864	460
T7	outcome 1020 1047	disease-free survival (DFS)
T8	outcome 1063 1084	overall survival (OS)
T9	outcome 1460 1470	DFS events
T12	outcome 1488 1497	basal-lik
T13	outcome 1547 1556	luminal B
T18	outcome 1700 1709	luminal A
T19	outcome 1620 1667	Human epidermal growth factor receptor-enriched
T10	outcome 1169 1179	DFS and OS
